Retrospective study of patients with metastatic triple-negative breast cancer: Survival, health care utilization, and cost

Community Oncology

Volumn 9, Issue 1, 2012, Pages 8-14

  Baser, Onur ^a,b   Wei, Wenhui ^c   Xie, Lin ^b   Henk, Henry J ^d   Teitelbaum, April ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b STATINMED RESEARCH   (United States)

^c SANOFI   (France)

^d i3Innovus   (United States)

^e i3Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; METASTASIS; RETROSPECTIVE STUDY; SOCIAL SECURITY; SURVIVAL RATE; TRIPLE NEGATIVE BREAST CANCER;

EID: 84856670879     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmonc.2011.10.002     Document Type: Article

References (18)

1. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology. 2008;22(11):1233-1239.
2. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
3. Schneider BP, Winer EP, Foulkes WD, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008; 14(24):8010-8018.
4. Swain S. Triple-negative breast cancer: metastatic risk and role of platinum agents. Paper presented at: Annual Meeting of the American Society for Clinical Oncology, Clinical Science Symposium; June 3, 2008; Chicago, IL.
5. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15, pt 1):4429-4434.
6. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer V.2.2010. Fort Washington, PA: NCCN; 2011. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed March 1, 2011.
7. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638-2645.
8. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009; 27(8):1168-1176.
9. Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value Health. 2008; 11(2):213-220.
10. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index, Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999-2008. Med Care. Series ID: SUUR0000SAM. Washington, DC: US Dept. of Labor, Bureau of Labor Statistics, 2008. http://data.bls.gov/cgi-bin/surveymost?su.
11. Lin DY. Linear regression analysis of censored medical cost data. Biostatistics. 2000;1(1):35-47.
12. Baser O, Gardiner JC, Bradley CJ, Yüce H, Given C. Longitudinal analysis of censored medical cost data. Health Econ. 2006;15(5):513-525.
13. Billar JA, Dueck AC, Stucky CC, et al. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol. 2010;17(suppl 3):384-390.
14. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and HER2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1-2):4-13.
15. Whitworth A. New research suggests access, genetic differences play role in high minority cancer death rate. J Natl Cancer Inst. 2006;98(10):669.
16. Kapp JM, Walker R, Haneuse S, Buist DS, Yankaskas BC. Are there racial/ethnic disparities among women younger than 40 undergoing mammography? Breast Cancer Res Treat. 2010;124(1): 213-222.
17. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100(12):888-897.
18. Dahlberg L, Lundkvist J, Lindman H. Health care costs for treatment of disseminated breast cancer. Eur J Cancer. 2009;45(11): 1987-1991.